Search

To evaluate the dosimetry, clinical outcomes, and toxicity of patients treated with stereotactic body radiotherapy (SBRT) for adrenal metastases.

To present clinical outcomes, early toxicity, and dosimetric constraints for patients undergoing stereotactic body radiation therapy (SBRT) for abdominal or pelvic tumors.

In this retrospective study we determined the results of salvage external beam radiation therapy (RT) to the prostate bed for isolated increase of serum prostate specific antigen (PSA) after radical prostatectomy.

Although endometrial cancer continues to be the most prevalent gynecologic malignancy in the United States, optimal adjuvant treatment for stage I adenocarcinoma remains uncertain. Five-year survival rates as high as 90% are reported in women given adjuvant radiation therapy (RT) in conjunction with surgical removal. Poorer outcomes are recorded for those having stage IC disease (more than 50% myometrial invasion) or grade 3 or 4 adenocarcinoma. This retrospective analysis is based on data from the Surveillance, Epidemiology, and End Results (SEER) program of the U.S. National Cancer Institute for the years 1988 through 2001. The study population included 21,249 women with an average age of 63 years who had American Joint Committee on Cancer stage IA–C node-negative endometrial adenocarcinoma. All participants underwent total abdominal hysterectomy and bilateral salpingooophorectomy.